NOV-002, a mimetic of glutathione disulfide.
BACKGROUND
Oxidative signaling to modulate redox-sensitive cell functions is a heretofore unexploited approach to developing new drugs for poorly treated oncology indications, where current therapies are often only palliative and accompanied by severe toxicities.


OBJECTIVE
Clinical and non-clinical findings with NOV-002 (a mimetic of glutathione disulfide that represents such an approach) are reviewed and evaluated.


METHODS
Published data on NOV-002 along with unpublished information from the drug's sponsor were reviewed. Literature analysis also focused on protein S-glutathionylation as a regulatory mechanism, particularly in relation to cell signaling, proliferation and cytoskeletal architecture.


CONCLUSIONS
NOV-002 is a mechanistically novel agent with potential for ameliorating hematologic toxicity and enhancing efficacy when used in combination with standard chemotherapy to treat cancer patients.
Townsend
Danyelle M
DM
Medical University of South Carolina, Department of Pharmaceutical Sciences, 173 Ashley Avenue, PO Box 250505, Charleston, SC 29425, USA.
Pazoles
Christopher J
CJ
Tew
Kenneth D
KD
D000818:Animals; D002945:Cisplatin / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D004338:Drug Combinations; D004361:Drug Tolerance; D019803:Glutathione Disulfide / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D018716:Molecular Mimicry; D015394:Molecular Structure
D004338:Drug Combinations; C529375:NOV 002; D002945:Cisplatin; D019803:Glutathione Disulfide